Dare Bioscience reports Q3 loss and revenue miss

Dare Bioscience reported third-quarter GAAP EPS of -$0.18, missing estimates by $0.02. Revenue was $47.63K, below the $1.82M consensus and higher than $2,300 a year earlier in the company-reported figures.

The results give investors a quarterly earnings and revenue miss, with revenue materially below consensus. The disclosed shortfalls may weigh on the market’s assessment of the company’s near-term performance.

  • 1Third-quarter GAAP EPS was -$0.18, a $0.02 miss versus estimates.
  • 2Third-quarter revenue was $47.63K versus a $1.82M consensus estimate.
  • 3Revenue was reported as $48,000 versus $2,300 a year earlier.

Sources